北美噬菌体治疗市场，按目标（大肠杆菌、葡萄球菌、链球菌、假单胞菌、沙门氏菌等）、类型（溶菌性、溶源性）、基础（无菌肉汤培养物、水溶性果冻基础）、应用（细菌性痢疾、皮肤和鼻粘膜感染、化脓性皮肤感染、肺和胸膜感染、术后伤口感染等）、给药途径（口服、肠胃外、直肠、皮肤、其他）、最终用户（医院、专科诊所、学术研究和机构、其他）、分销渠道（直接招标、第三方分销商）、国家（美国、加拿大、墨西哥）划分 - 行业趋势和预测到 2028 年。
市场分析与洞察：北美噬菌体治疗市场
北美噬菌体治疗市场预计将在 2021 年至 2028 年的预测期内实现市场增长。Data Bridge Market Research 分析称，在 2021 年至 2028 年的预测期内，市场将以 5.5% 的复合年增长率增长，预计到 2028 年将达到 2507 万美元。抗生素耐药性感染的日益流行和技术进步是推动预测期内市场需求的主要驱动因素。然而，治疗相关的高成本和熟练专业人员的短缺是预计在预测期内制约市场增长的因素。
噬菌体，也称为噬菌体或细菌病毒，是一组感染细菌并用于治疗细菌感染的病毒。当细菌产生耐药性时，这可以用作抗生素的替代品。噬菌体比抗生素更具特异性。它们通常不仅对宿主生物无害，而且对其他有益细菌（如肠道微生物群）也无害，从而减少了机会性感染的机会。新型药物管道的存在、市场参与者的战略举措以及医疗保健行业支出的增加预计将为市场提供有利可图的增长机会。然而，噬菌体疗法的局限性和缺乏适当的监管指南是市场增长面临的主要挑战。
噬菌体治疗市场报告提供了市场份额、新发展和产品线分析的详细信息，国内和本地市场参与者的影响，分析了新兴收入领域、市场法规变化、产品批准、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情况，请联系我们获取分析师简报。我们的团队将帮助您创建收入影响解决方案，以实现您的预期目标。
北美噬菌体治疗市场范围和市场规模
噬菌体治疗市场根据目标、类型、基础、应用、给药途径、最终用户和分销渠道进行细分。细分市场之间的增长有助于您分析利基增长点和进入市场的策略，并确定您的核心应用领域和目标市场的差异
- 根据目标，北美噬菌体治疗市场细分为大肠杆菌、葡萄球菌、链球菌、假单胞菌、沙门氏菌等。由于葡萄球菌感染患病率上升以及私人和公共资金增加，预计 2021 年葡萄球菌细分市场将占据市场主导地位。
- 根据类型，北美噬菌体治疗市场分为溶菌噬菌体和溶原噬菌体。2021 年，溶菌噬菌体预计将占据市场主导地位，因为它具有作用特异性和活性范围窄。
- 根据基质，北美噬菌体治疗市场细分为无菌肉汤培养、水溶性果冻基质。2021 年，无菌肉汤培养预计将占据市场主导地位，因为它可以评估活体微生物，并易于定量培养基中的细胞。
- 根据应用，北美噬菌体治疗市场细分为细菌性痢疾、皮肤和鼻粘膜感染、化脓性皮肤感染、肺和胸膜感染、术后伤口感染等。2021 年，由于心脏手术、腿部手术等手术数量增加，以及导致手术的道路交通事故数量增加，预计术后伤口领域将占据市场主导地位。
- 根据给药途径，北美噬菌体治疗市场分为口服、肠外、直肠、皮肤和其他。2021 年，口服给药由于给药方便快捷，预计将占据市场主导地位。
- 根据最终用户，北美噬菌体治疗市场分为医院、专科诊所、学术研究和机构等。预计到 2021 年，医院部门将因患者满意度提高和成本降低而占据市场主导地位。
- 根据分销渠道，北美噬菌体治疗市场分为直销和第三方分销商。2021 年，直接招标部分预计将占据市场主导地位，因为它可以实现成本节约并提高效率。
噬菌体治疗市场国家层面分析
分析噬菌体治疗市场，并根据目标、类型、基础、应用、给药途径、最终用户和分销渠道提供市场规模信息
强迫症药物市场报告涉及的国家包括美国、加拿大和墨西哥。
由于研发活动的增加和政府资金的增加，预计北美地区的溶解部分将在 2021 年至 2028 年的预测期内以最高增长率增长。在北美，由于强大的研究基础设施，预计美国将在预测期内占据市场主导地位。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了北美品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀少竞争而面临的挑战、销售渠道的影响。
私营部门资金的增加和技术的进步正在推动噬菌体治疗市场的增长。
噬菌体治疗市场还为您提供每个国家噬菌体治疗产品行业增长的详细市场分析，包括药物销售、进步、技术和监管环境变化对噬菌体治疗市场的支持的影响。数据涵盖 2011 年至 2019 年的历史时期。
竞争格局和噬菌体治疗市场份额分析
噬菌体治疗市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对强迫症药物市场的关注有关。
全球噬菌体治疗市场的主要公司有 Microgen、Micreos、ATCC、INTRALYTIX、Adaptive Phage Therapeutics、Armata pharmaceuticals Inc.、Locus Biosciences, INC.、Delmont Laboratories, INC.、Nextbiotics、Pherecydes Pharma、Pylum、iNTODEWORLD, INC.、Enbiotix、Fixed-Phage Limited 和 Cytophage Technologies Inc 等。
全球各地的许多公司也发起了多项产品发布和协议，这也加速了噬菌体治疗市场的发展。
例如，
- 2020 年 4 月，Phagelux, Inc. 宣布，该公司已与 DCM 达成多项商业合作，包括其 AgriPhage 系列生物农药的欧洲销售、营销和产品开发合作等。这有助于该公司充分探索和开发下一代噬菌体
- 2020 年 7 月，Intralytix, Inc. 宣布该公司已从美国专利商标局获得志贺氏菌噬菌体及其应用的专利。该公司进一步补充说，该专利涵盖了各个领域，例如这些制剂的具体用途、几种对志贺氏菌具有强溶解力的噬菌体及其各种制剂。这有助于该公司在预定期限内提供保护，从而阻止竞争对手
- 2021 年 6 月，Adaptive Phage Therapeutics 宣布启动噬菌体疗法 (Phage Bank) 的 1/2 期研究，以评估针对性个性化噬菌体 (“噬菌体”) 治疗对泌尿道感染 (UTI) 患者的安全性、耐受性和有效性。这有助于该公司开发一种针对多种耐多药细菌感染的新型治疗方法。
市场参与者的合作、产品发布、业务扩展、奖励和认可、合资企业和其他策略正在增强公司在噬菌体治疗市场中的市场，这也为组织改进其噬菌体治疗产品提供了好处。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA BACTERIOPHAGES THERAPY MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TAREGET LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTERS FIVE FORCES MODEL
4.2 PESTEL ANALYSIS
5 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: REGULATIONS
5.1 THE U.S. REGULATORY GUIDELINES FOR BACTERIOPHAGES
5.2 EUROPE REGULATORY GUIDELINE FOR BACTERIOPHAGE
5.3 JAPAN REGULATORY GUIDELINE FOR BACTERIOPHAGE
5.4 AUSTRALIA REGULATORY GUIDELINE FOR BACTERIOPHAGE
6 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: REGIONAL SUMMARY
7 RESEARCH AND DEVELOPMENT ANALYSIS: NORTH AMERICA BACTERIOPHAGES THERAPY MARKET
7.1 PIPELINE ANALYSIS
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 INCREASING PREVALENCE OF ANTIBIOTIC-RESISTANT INFECTIONS
8.1.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
8.1.3 INCREASING GOVERNMENT FUNDING
8.1.4 INCREASING PRIVATE SECTOR FUNDING
8.1.5 TECHNOLOGICAL ADVANCEMENTS
8.2 RESTRAINTS
8.2.1 HIGH COST ASSOCIATED WITH BACTERIOPHAGE THERAPY
8.2.2 LACK OF SKILLED PROFESSIONALS
8.2.3 SIDE-EFFECTS OF BACTERIOPHAGE THERAPY
8.2.4 AVAILABILITY OF ALTERNATIVE THERAPIES FOR ANTIBIOTIC RESISTANCE
8.3 OPPORTUNITIES
8.3.1 PRESENCE OF NOVEL PIPELINE DRUGS
8.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
8.3.3 INCREASING HEALTHCARE EXPENDITURE
8.4 CHALLENGES
8.4.1 LIMITATIONS OF BACTERIOPHAGE THERAPY
8.4.2 LACK OF PROPER REGULATORY GUIDELINES
9 IMPACT OF COVID-19 ON NORTH AMERICA BACTERIOPHAGES THERAPY MARKET
9.1 IMPACT ON THE PRICE
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY
9.4 STRATEGIC INITIATIVES BY MANUFACTURERS
9.5 CONCLUSION
10 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TARGET
10.1 OVERVIEW
10.2 STAPHYLOCOCCUS
10.3 ESCHERICHIA COLI
10.4 PSEUDOMONAS
10.5 STREPTOCOCCUS
10.6 SALMONELLA
10.7 OTHERS
11 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TYPE
11.1 OVERVIEW
11.2 LYTIC
11.3 LYSOGENIC
12 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY BASE
12.1 OVERVIEW
12.2 STERILE BROTH CULTURE
12.3 WATER-SOLUBLE JELLY BASE
13 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION
13.1 OVERVIEW
13.2 POSTOPERATIVE WOUND INFECTIONS
13.3 INFECTIONS OF SKIN AND NASAL MUCOSA
13.4 BACTERIAL DYSENTERY
13.5 SUPPURATIVE SKIN INFECTIONS
13.6 LUNG AND PLEURAL INFECTION
13.7 OTHERS
14 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 ORAL
14.2.1 LIQUID
14.2.2 TABLET
14.3 DERMAL
14.4 PARENTERAL
14.4.1 INTRAVENOUSLY
14.4.2 INTRAPLEURAL INJECTIONS
14.5 OTHERS
15 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 SPECILAITY CLINICS
15.4 ACADEMIC RESEARCH & INSTITUTES
15.5 OTHERS
16 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 THIRD PARTY DISTRIBUTORS
17 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY REGION
17.1 NORTH AMERICA
17.1.1 U.S.
17.1.2 CANADA
18 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
18.3 COMPANY SHARE ANALYSIS: EUROPE
18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
19 SWOT ANALYSIS
20 COMPANY PROFILE
20.1 MICROGEN
20.1.1 COMPANY SNAPSHOT
20.1.2 COMPANY SHARE ANALYSIS
20.1.3 PRODUCT PORTFOLIO
20.1.4 RECENT DEVELOPMENTS
20.2 ADAPTIVE PHAGE THERAPEUTICS
20.2.1 COMPANY SNAPSHOT
20.2.2 COMPANY SHARE ANALYSIS
20.2.3 PRODUCT PORTFOLIO
20.2.4 RECENT DEVELOPMENTS
20.3 PHAGELUX,INC
20.3.1 COMPANY SNAPSHOT
20.3.2 COMPANY SHARE ANALYSIS
20.3.3 PRODUCT PORTFOLIO
20.3.4 RECENT DEVELOPMENTS
20.4 LOCUS BIOSCIENCES, INC.
20.4.1 COMPANY SNAPSHOT
20.4.2 COMPANY SHARE ANALYSIS
20.4.3 PRODUCT PORTFOLIO
20.4.4 RECENT DEVELOPMENTS
20.5 ATCC
20.5.1 COMPANY SNAPSHOT
20.5.2 COMPANY SHARE ANALYSIS
20.5.3 PRODUCT PORTFOLIO
20.5.4 RECENT DEVELOPMENTS
20.6 INTRALYTIX, INC.
20.6.1 COMPANY SNAPSHOT
20.6.2 PRODUCT PORTFOLIO
20.6.3 RECENT DEVELOPMENTS
20.7 MICREOS
20.7.1 COMPANY SNAPSHOT
20.7.2 PRODUCT PORTFOLIO
20.7.3 RECENT DEVELOPMENT
20.8 PYLUM
20.8.1 COMPANY SNAPSHOT
20.8.2 TECHNOLOGY PORTFOLIO
20.8.3 RECENT DEVELOPMENTS
20.9 FIXED-PHAGE LIMITED
20.9.1 COMPANY SNAPSHOT
20.9.2 PRODUCT PORTFOLIO
20.9.3 RECENT DEVELOPMENTS
20.1 ARMATA PHARMACEUTICALS, INC.
20.10.1 COMPANY SNAPSHOT
20.10.2 PRODUCT PORTFOLIO
20.10.3 RECENT DEVELOPMENTS
20.11 ARTHUR ANDREW MEDICAL
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLIO
20.11.3 RECENT DEVELOPMENT
20.12 CYTOPHAGE TECHNOLOGIES INC.
20.12.1 COMPANY SNAPSHOT
20.12.2 PRODUCT PORTFOLIO
20.12.3 RECENT DEVELOPMENT
20.13 ENBIOTIX, INC.
20.13.1 COMPANY SNAPSHOT
20.13.2 PRODUCT PORTFOLIO
20.13.3 RECENT DEVELOPMENTS
20.14 INTODEWORLD, INC.
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENT
20.15 NEXTBIOTICS
20.15.1 COMPANY SNAPSHOT
20.15.2 TECHNOLOGY PORTFOLIO
20.15.3 RECENT DEVELOPMENT
20.16 PHERECYDES PHARMA
20.16.1 COMPANY SNAPSHOT
20.16.2 PRODUCT PORTFOLIO
20.16.3 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 2 NORTH AMERICA STAPHYLOCOCCUS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 3 NORTH AMERICA ESCHERICHIA COLI IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 NORTH AMERICA PSEUDOMONAS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 NORTH AMERICA STREPTOCOCCUS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 NORTH AMERICA SALMONELLA IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 NORTH AMERICA OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 9 NORTH AMERICA LYTIC IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA LYSOGENIC IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA STERILE BROTH CULTURE IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA WATER-SOLUBLE JELLY BASE IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA POSTOPERATIVE WOUND INFECTIONS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA INFECTIONS OF SKIN AND NASAL MUCOSA IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA BACTERIAL DYSENTERY IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA SUPPURATIVE SKIN INFECTIONS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 NORTH AMERICA LUNG AND PLEURAL INFECTION IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 22 NORTH AMERICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 NORTH AMERICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA DERMAL IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 27 NORTH AMERICA OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 29 NORTH AMERICA HOSPITALS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA SPECILIATY CLINICS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA ACADEMIC RESEARCH & INSTITUTES IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 NORTH AMERICA OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 34 NORTH AMERICA DIRECT TENDER IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 NORTH AMERICA THIRD PARTY DISTRIBUTORS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 37 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 38 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 39 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 40 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 41 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 42 NORTH AMERICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 43 NORTH AMERICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 44 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 45 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 46 U.S. BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 47 U.S. BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 48 U.S. BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 49 U.S. BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 50 U.S. BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 51 U.S. ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 52 U.S. PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 53 U.S. BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 54 U.S. BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 55 CANADA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 56 CANADA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 57 CANADA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 58 CANADA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 59 CANADA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 60 CANADA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 61 CANADA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 62 CANADA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 63 CANADA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET : NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: SEGMENTATION
FIGURE 11 RISING INCIDENCE OF ANTIBIOTIC-RESISTANT INFECTIONS AND TECHNOLOGICAL ADVANCEMENTS ARE EXPECTED TO DRIVE THE NORTH AMERICA BACTERIOPHAGES THERAPY MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 STAPHYLOCOCCUS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA BACTERIOPHAGES THERAPY MARKET IN 2021 & 2028
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA BACTERIOPHAGES THERAPY MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA BACTERIOPHAGES THERAPY MARKET
FIGURE 15 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY TARGET, 2020
FIGURE 16 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY TARGET, 2021-2028 (USD MILLION)
FIGURE 17 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY TARGET, CAGR (2021-2028)
FIGURE 18 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY TARGET, LIFELINE CURVE
FIGURE 19 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY TYPE, 2020
FIGURE 20 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY TYPE, 2021-2028 (USD MILLION)
FIGURE 21 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 22 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY BASE, 2020
FIGURE 24 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY BASE, 2021-2028 (USD MILLION)
FIGURE 25 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY BASE, CAGR (2021-2028)
FIGURE 26 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY BASE, LIFELINE CURVE
FIGURE 27 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, 2020
FIGURE 28 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, 2021-2028 (USD MILLION)
FIGURE 29 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 30 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 31 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 32 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
FIGURE 33 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 34 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY END USER, 2020
FIGURE 36 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY END USER, 2021-2028 (USD MILLION)
FIGURE 37 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY END USER, CAGR (2021-2028)
FIGURE 38 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 40 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
FIGURE 41 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 42 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: SNAPSHOT (2020)
FIGURE 44 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020)
FIGURE 45 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2021 & 2028)
FIGURE 46 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020 & 2028)
FIGURE 47 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY TARGET (2021-2028)
FIGURE 48 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: COMPANY SHARE 2020 (%)
FIGURE 49 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: COMPANY SHARE 2020 (%)
FIGURE 50 EUROPE BACTERIOPHAGES THERAPY MARKET: COMPANY SHARE 2020 (%)
FIGURE 51 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET: COMPANY SHARE 2020 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
